Article ID: EJ26-0221
Muscle impairment, characterized by reduced muscle quality and functional performance, may persist in patients with Cushing’s syndrome (CS) in remission and acromegaly (ACRO) after long-term biochemical control. This study evaluated whether rectus femoris ultrasonography (US), using standardized thickness and volume measurements and semi-quantitative Heckmatt echogenicity grading, identifies residual muscle quality abnormalities in these patients and whether US findings relate to magnetic resonance imaging (MRI)-derived fat fraction (FF), functional performance, and patient-reported outcomes. We studied 36 women with CS in remission, 36 patients with long-term controlled ACRO, and 64 unique healthy controls used for disease-specific matched comparisons. Rectus femoris and vastus intermedius US assessed muscle size and echogenicity at mid-thigh and distal-third sites. MRI FF was measured using a 2-point Dixon sequence. Physical performance was assessed by gait speed, timed up-and-go, 30-second chair-stand, and handgrip strength tests. Quality of life (QoL) was assessed using CushingQoL, AcroQoL, and the 36-Item Short Form Health Survey (SF-36). Rectus femoris echogenicity was higher in both patient groups than in matched controls despite similar US muscle size. Higher echogenicity correlated with MRI-derived thigh FF and with selected measures of poorer physical performance. Associations with QoL were exploratory and were strongest for physical functioning-related domains, although broader disease-related and psychosocial contributors cannot be excluded. These findings support muscle US as a feasible adjunct to biochemical follow-up and MRI for identifying residual myopathy in controlled pituitary disease. Longitudinal and multicenter studies using standardized quantitative US protocols are needed to define reproducibility and clinical thresholds.